Boulevard emerged from stealth with approximately $65 million in launch financing to develop B cell-directed multi-specific antibody therapies, backed entirely by Deerfield Management. The clinical-stage company’s lead program, BLVD101, is a bispecific antibody targeting BAFF and APRIL with a stated goal of more durable autoimmune control. Boulevard is initially evaluating BLVD101 in IgA nephropathy and highlighted the possibility of quarterly dosing intervals based on early interim Phase 1 data referenced from healthy volunteers. Beyond BLVD101, the company said it is advancing three multi-specific antibody programs through a precision immunology platform focused on aligning B cell biology with indications. The structure of the launch—incubation inside Deerfield Discovery and Development before spinning out—suggests a more internally validated pipeline-to-clinic approach than typical venture syndication, with Deerfield affiliates serving as the primary backer. For investors and therapeutics builders, Boulevard’s emphasis on reduced dosing burden in chronic autoimmune disease reflects growing interest in regimen convenience as a differentiation lever, not just target selection.